Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin’s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
The company has a market cap of 677.82 million, with 574.43 million shares outstanding. Cell Therapeutics has a 3 year sales growth of 386% and its last quarter earnings per share rose 96%. The company ended the week trading at $1.18 up $0.07 or 6.31% on the upside with lighter than average trading volume of 63.79 million. The average weekly trading volume for Cell Therapeutics is 83.97 million.
*** Please have a look at the chart below ***